Skip to Content
Home > Clinical Trials Search Results
View Additional Section Content
NCT00774345. (Accrual limited to Abington Cancer Care Specialists.)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in patients with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population. (NCT01466153)
My AH Link
© 2015 Abington Health. All rights reserved.
1200 Old York Road, Abington, PA 19001